Abstract Objective To evaluate the efficacy of neoadjuvant therapy plus surgery and surgery plus postoperative adjuvant therapy for phase Ⅱ and Ⅲ low rectal cancer. Methods A retrospective analysis was performed on the clinical data of patients with phase Ⅱ and Ⅲ(T3, T4 and/or N1, N2) low rectal cancer who were admitted to our hospital from 2009 to 2013.Those patients were divided into group A (n=98) and group B (n=93) according to the treatment method. Group A received neoadjuvant therapy followed by radical resection. Group B was treated with radical resection and postoperative adjuvant therapy. Between-group comparison was made by χ2 test or Fisher′s exact probability test. The Kaplan-Meier method was used to analyze the survival rates. Results The follow-up rate was 92.1%.The 3-year local recurrence (LR) and distant metastasis (DM) rates were significantly lower in group A than in group B (12.9% vs. 32.2%,P=0.002;13.5% vs. 37.8%,P=0.001).The 3-year overall survival and disease-free survival rates were significantly improved in group A than in group B (84.7% vs. 69.9%,P=0.022;77.6% vs. 50.3%,P=0.004). Conclusions Neoadjuvant therapy is a safe and reliable treatment approach for phase Ⅱ and Ⅲ low rectal cancer, which can significantly reduce LR and DM rates and prolong the survival time.
Palida·Apiziaji,Ayiguli·Hare,Yisikada·Abulimiti et al. Ⅱ and Ⅲ rectal cancer neoadjuvant treatment evaluation[J]. Chinese Journal of Radiation Oncology, 2016, 25(12): 1310-1313.
Palida·Apiziaji,Ayiguli·Hare,Yisikada·Abulimiti et al. Ⅱ and Ⅲ rectal cancer neoadjuvant treatment evaluation[J]. Chinese Journal of Radiation Oncology, 2016, 25(12): 1310-1313.
[1] Bellows CF,Jaffe B,Bacigalupo L,et al. Clinical significance of magnetic resonance imaging findings in rectal cancer[J].World J Radiol,2011,3(4):92-104.10.4329/wjr.v3.i4.92. [2] 杜潇,程中,周总光.局部进展期低位直肠癌新辅助治疗[J].中华胃肠外科杂志,2012,15(10):1095-1098.10.3760/cma.j.issn.1671-0274.2012.10.032. Du X,Cheng Z,Zhou ZG.Neo-adjuvant therapy for locally advanced low rectal cancer[J].Chin J Gastrointest Surg,2012,15(10):1095-1098.10.3760/cma.j.issn.1671-0274.2012.10.032. [3] 许金全,邹菁帆,吴碧川,等.术前同步放化疗在局部晚期直肠癌治疗中的价值[J].临床肿瘤学杂志,2010,15(8):733-735.10.3969/j.issn.1009-0460.2010.08.014. Xu JJ,Zou JF,Wu BC,et al. Effect of neoadjuvant therapy on local advanced rectal cancer[J].Chin Clin Oncol,2010,15(8):733-735.10.3969/j.issn.1009-0460.2010.08.014. [4] Marijnen CAM,Glimelius B.The role of radiotherapy in rectal cancer[J].Eur J Cancer,2002,38(7):943-952.10.1016/S0959-8049(02)00047-3. [5] Sauer R,Liersch T,Merkel S,et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer:results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after a median follow-up of 11 years[J].J Clin Oncol,2012,30(16):1926-1933.10.1200/JCO.2011.40.1836. [6] 周铃,李卫,王颖.中、低位直肠癌新辅助放疗 30例临床分析[J].重庆医学,2011,40(31):3152-3153.10.3969/j.issn.1671-8348.2011.31.013. Zhou L,Li W,Wang Y.Clinical analysis of neoadjuvant radiotherapy for middle and lower rectal cancer in 30 cases[J].Chongqing Med,2011,40(31):3152-3153.10.3969/j.issn.1671-8348.2011.31.013. [7] 胡克,李文博,侯晓荣,等.局部进展期直肠癌术前新辅助治疗疗效分析[J].中华放射肿瘤学杂志,2011,20(6):502-505.10.3760/cma.j.issn.1004-4221.2011.06.016. Hu K,Li WB,Hou XR,et al. The efficacy of neoadjuvant concurrent chemoradiotherapy or radiotherapy alone in patients with locally advanced rectal cancer[J].Chin J Radiat Oncol,2011,20(6):502-505.10.3760/cma.j.issn.1004-4221.2011.06.016. [8] 雒红军.术前新辅助治疗应用于直肠癌效果分析[J].实用临床医学,2014,15(8):47-48. Chu HJ.Preoperative neoadjuvant therapy for rectal cancer[J].Pract Clin Med,2014,15(8):47-48. [9] 柴宇啸,曲兴龙,王奕静,等.同步新辅助放化疗联合全直肠系膜切除术治疗中低位局部进展期直肠癌的临床研究[J].肿瘤,2011,31(7):658-661.10.3781/j.issn.1000-7431.2011.07.016. Chai YX,Qu XL,Wang YJ,et al. Neoadjuvant concurrent chemoradiotherapy combined with total mesorectal excision in the treatment of locally advanced middle and lower rectal cancer[J].Tumor,2011,31(7):658-661.10.3781/j.issn.1000-7431.2011.07.016. [10] Braendengen M,Tveit KM,Berglund A,et al. Randomized phase Ⅲ study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer[J].J Clin Oncol,2008,26(22):3687-3694.10.1200/JCO.2007.15.3858. [11] Gerard JP,Rostom Y,Gal J,et al. Can we increase the chance of sphincter saving surgery in rectal cancer with neoadjuvant treatments:lessons from a systematic review of recent randomized trials[J].Crit Rev Oncol Hematol,2012,81(1):21-28.10.1016/j.critrevonc.2011.02.001.
2016, Vol. 25 
